DGAP-Adhoc: BRAIN Biotech AG: BRAIN-Engineered-Cas (BEC) Thought to be a Patentable Technology

DGAP-Advert-hoc: BRAIN Biotech AG / Key be conscious(s): Patent

BRAIN Biotech AG: BRAIN-Engineered-Cas (BEC) Thought to be a Patentable Technology

11-Jan-2022 / 18: 47 CET/CEST

Disclosure of an within data acc. to Article 17 MAR of the Legislation (EU) No 596/2014, transmitted by DGAP – a provider of EQS Group AG.

The issuer is fully accountable for the stutter material of this announcement.

BRAIN-Engineered-Cas (BEC) Thought to be a Patentable Technology

Zwingenberg, Germany, January 11th, 2022. BRAIN Biotech AG („BRAIN“) obtained an global search document and a written thought from the European Patent Place of job (EPO) as global buying authority (ISA). The favorable written thought states that the BRAIN-Engineered-Cas (BEC) nucleases for which patent protection is sought under the Patent Company Treaty (PCT) are – referring to the BEC nuclease sequences – inventive, are industrially appropriate and are additionally now not otherwise excluded from patent protection. Hence, the respective sequences of the BEC nucleases are actually apt patentable by the EPO.

The patent utility and the search document are anticipated to be published by the WIPO quickly after January 21st, 2022. After the e-newsletter the frequent patent approval direction of including the opposition complaints duration after grant will rob its direction.

Notifying particular person:

Michael Schneiders, Head of IR & Sustainability

BRAIN Biotech AG

Darmstädter Str. 34-36, 64673 Zwingenberg, Germany


Investor Relatives Place of job

Tel.: +49-(0)-6251-9331-0

Fax: +49-(0)-6251-9331-11

E-Mail: ir@mind-biotech.com

Pause of advert hoc announcement

Info and Rationalization of the Issuer to this News:


BRAIN Biotech AG (‚BRAIN‘) is a main European specialist in industrial biotechnology. As a technology supplier and developer of bio-primarily based mostly products and alternatives for nutrition, well being and the atmosphere, the company helps the biologization of industry and contributes to a extra sustainable economic system. BRAIN is the dad or mum company of the BRAIN Group. Two pillars bear BRAIN Group’s enterprise: The BioScience segment consists of contract compare for infamous industrial companions as well to an incubator for the pattern of the company’s delight in extremely modern products. Within the BioIndustrial segment, the company makes a speciality of uniqueness enterprise in the manufacturing and refinement of enzymes, microorganisms and bioactive natural products and the respective distribution.

The BRAIN Group maintains its delight in various series of natural sources: the BRAIN Bioarchive contains microorganisms, genetic self-discipline cloth and natural substances. In accordance to this series and with a comprehensive technology portfolio, BRAIN addresses technological challenges and develops bio-primarily based mostly products and alternatives that are already successfully employed in the industry. The BRAIN Group has its delight in manufacturing products and providers in Germany, UK and the US, which along with the connected biotechnological manufacturing abilities, total the price chain one day of the Group.

As a Participant of the United Nations Global Compact, BRAIN Biotech AG is dedicated to aligning recommendations and operations with current solutions on human rights, labour, atmosphere and anti-corruption, and rob actions that arrive societal targets.

Since its IPO in 2016, BRAIN Biotech AG has been listed in the High Long-established of the Frankfurt Stock Change (ISIN DE0005203947 / WKN 520394).

11-Jan-2022 CET/CEST The DGAP Distribution Companies and products consist of Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.dgap.de

Zur Quelle

Von admin

Schreibe einen Kommentar

Deine E-Mail-Adresse wird nicht veröffentlicht.